A unique study in malignant pleural/peritoneal effusions [68] demonstrated that intrapleural rAd-p53 gene therapy alongside cisplatin significantly improved effusion control rates (63.0% vs. 42.9%, p < 0.05). This evidence concerns the gene TP53 and Ascites.